Pfizer set to inject a further $500m into $100m gene therapy manufacturing site

Pfizer is pushing the pedal towards producing the first major gene therapies, with this huge money injection set to send progress into overdrive. The manufacturing site will also employ a further 300 employees.

The larger plant will provide a large addition to its clinical and commercial scale production capabilities for its work on potential genetic cures using recombinant adeno-associated virus vectors.

The manufacturing plant started out at a much smaller scale when Pfizer acquired the plant in Sanford from biotech Bamboo Therapeutics. At the time it was expected to employee around 40 scientists, with this expansion increasing jobs by a further 300, this will increase the Pfizer headcount to an impressive 650.

Things are starting to come together now for Pfizer as this expansion will no doubt help towards its future gene therapy products in the pipeline. With Pfizer announcing last month positive results on the durability of responses to their haemophilia A gene therapy. With the confidential review also giving encouragement to those who believe that it will outperform rival products from Spark Therapeutics and BioMarin.

No comments:

Post a Comment

Coranavirus and its relationship with IP exclusivity

With the global shutdown that has occurred due to COVID-19, its presence has caused long-lasting effects in all aspects of our lives and t...